Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Best in class 2and 3 year data

<< Previous

Bullboard Posts

Next >>

Post by enriquesuaveon Oct 13, 2024 8:31pm

430 Views

Post# 36264867

Best in class 2and 3 year data

so far we beat all competitors on 2 and 3 year data and by far. J&J tar 200 is down to 4.7% at 3 years and we are aiming for 21.4% as per Kaplan Meyer projections so far.. This shows how all other treatments show rapidly declining CR rates once they stop treating. We also beat 2 years data of recently approved combination treatment Anktiva/ BCG. 24%% vs 25.6% for us based on Kaplan Meyer projection. Can the FDA give us AA or even full approval right away?

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals